Research programme: cancer therapeutics - Arisaph Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - Arisaph Pharmaceuticals

Alternative Names: ARI-3996; ARI-6000; Immune stimulation/vaccines - Arisaph; Tumour activated pro-drugs - Arisaph; Tumour activated pro-soft drugs - Arisaph; Ultra-smart pro-drugs - Arisaph; Ultra-smart pro-soft drugs - Arisaph

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arisaph Pharmaceuticals
  • Developer Arisaph Pharmaceuticals; Fox Chase Cancer Center
  • Class Small molecules; Vaccines
  • Mechanism of Action Fibroblast activation protein antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
  • 29 Sep 2014 Arisaph Pharmaceuticals receives supplemental phase I and phase II STTR grant from the US National Cancer Institute for development of drug candidates using different technologies in Cancer
  • 31 Jul 2013 Arisaph Pharmaceuticals receives STTR grant from the US National Cancer Institute for development of small molecule immune modulators in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top